United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
1,400
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. United Therapeutics Corp market cap is $24.88B.
52 week high is the highest price of a stock in the past 52 weeks, or one year. United Therapeutics Corp 52 week high is $614.23 as of November 18, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. United Therapeutics Corp 52 week low is $455.63 as of November 18, 2026.
United Therapeutics Corp stock price today is $577.34.
United Therapeutics Corp stock price yesterday was $584.10.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. United Therapeutics Corp's P/E ratio is 22.04.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. United Therapeutics Corp P/B ratio is 3.9445.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. United Therapeutics Corp 50-day moving average is $546.33.